Skip to main content

Advertisement

SpringerLink
Log in

Neuro-oncology

Unmasking the multiforme in glioblastoma

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

Classification of glioblastomas into various molecular entities is required for the successful application of targeted therapeutics and personalized cancer therapy. Analyses of gene expression, genomic mutations and DNA copy number identified four molecular subtypes among histopathologically indistinguishable glioblastomas. This classification suggests the existence of distinct paths of tumor cell origin and variation in therapeutic sensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC–NCIC trial. Lancet Oncol. 10, 459–466 (2009).

    Article  CAS  Google Scholar 

  2. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).

  3. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110 (2010).

    Article  CAS  Google Scholar 

  4. Brennan, C. et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4, e7752 (2009).

    Article  Google Scholar 

  5. Colman, H. et al. A multigene predictor of outcome in glioblastoma. Neuro. Oncol. 12, 49–57 (2010).

    Article  CAS  Google Scholar 

  6. Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157–173 (2006).

    Article  CAS  Google Scholar 

  7. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, 21286, MD, USA

    C. Rory Goodwin

  2. Department of Neurology, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., 707 North Broadway, Baltimore, 21205, MD, USA

    John Laterra

Authors
  1. C. Rory Goodwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Laterra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Laterra.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goodwin, C., Laterra, J. Unmasking the multiforme in glioblastoma. Nat Rev Neurol 6, 304–305 (2010). https://doi.org/10.1038/nrneurol.2010.67

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2010.67

  • Springer Nature Limited

This article is cited by

Search

Navigation